Recent Advances in Understanding the Molecular Mechanisms of SGLT2 Inhibitors in Atrial Remodeling

被引：2

作者：

Minciuna, Ioan-Alexandru ^{[1
,2
]}

Tomoaia, Raluca ^{[1
,2
]}

Mihaila, Dragos ^{[1
]}

Cismaru, Gabriel ^{[1
,2
]}

Puiu, Mihai ^{[2
]}

Rosu, Radu ^{[1
,2
]}

Simu, Gelu ^{[1
,2
]}

Fringu, Florina ^{[1
,2
]}

Irimie, Diana Andrada ^{[1
,2
]}

Caloian, Bogdan ^{[1
,2
]}

Zdrenghea, Dumitru ^{[1
]}

Pop, Dana ^{[1
,2
]}

机构：

[1] Iuliu Hatieganu Univ Med & Pharm, Fac Med, Dept Internal Med 5, Cluj Napoca 400347, Romania

[2] Rehabil Hosp, Cardiol Dept, Cluj Napoca 400066, Romania

来源：

CURRENT ISSUES IN MOLECULAR BIOLOGY | 2024年 / 46卷 / 09期

关键词：

atrial remodeling; SGLT2; inhibitors; atrial fibrillation; atrial cardiomyopathy; heart failure; HEART-FAILURE;

D O I：

10.3390/cimb46090571

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Atrial cardiomyopathy and remodeling play pivotal roles in the development of atrial fibrillation (AF) and heart failure (HF), involving complex changes in atrial structure and function. These changes facilitate the progression of AF and HF by creating a dynamic interplay between mechanical stress and electrical disturbances in the heart. Sodium-glucose cotransporter 2 inhibitors (SGLT2is), initially developed for the management of type 2 diabetes, have demonstrated promising cardiovascular benefits, being currently one of the cornerstone treatments in HF management. Despite recent data from randomized clinical trials indicating that SGLT2is may significantly influence atrial remodeling, their overall effectiveness in this context is still under debate. Given the emerging evidence, this review examines the molecular mechanisms through which SGLT2is exert their effects on atrial remodeling, aiming to clarify their potential benefits and limitations. By exploring these mechanisms, this review aims to provide insights into how SGLT2is can be integrated into strategies for preventing the progression of atrial remodeling and HF, as well as the development of AF.

引用

页码：9607 / 9623

页数：17

共 61 条

[1]

Al Ghamdi Bandar, 2009, J Atr Fibrillation, V2, P125, DOI 10.4022/jafib.125

[2] Empagliflozin in Heart Failure with a Preserved Ejection Fraction [J].

Anker, Stefan D. ;

Butler, Javed ;

Filippatos, Gerasimos ;

Ferreira, Joao P. ;

Bocchi, Edimar ;

Boehm, Michael ;

Brunner-La Rocca, Hans-Peter ;

Choi, Dong-Ju ;

Chopra, Vijay ;

Chuquiure-Valenzuela, Eduardo ;

Giannetti, Nadia ;

Gomez-Mesa, Juan Esteban ;

Janssens, Stefan ;

Januzzi, James L. ;

Gonzalez-Juanatey, Jose R. ;

Merkely, Bela ;

Nicholls, Stephen J. ;

Perrone, Sergio V. ;

Pina, Ileana L. ;

Ponikowski, Piotr ;

Senni, Michele ;

Sim, David ;

Spinar, Jindrich ;

Squire, Iain ;

Taddei, Stefano ;

Tsutsui, Hiroyuki ;

Verma, Subodh ;

Vinereanu, Dragos ;

Zhang, Jian ;

Carson, Peter ;

Lam, Carolyn Su Ping ;

Marx, Nikolaus ;

Zeller, Cordula ;

Sattar, Naveed ;

Jamal, Waheed ;

Schnaidt, Sven ;

Schnee, Janet M. ;

Brueckmann, Martina ;

Pocock, Stuart J. ;

Zannad, Faiez ;

Packer, Milton .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (16) :1451-1461

[3] SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction [J].

Avula, Vennela ;

Sharma, Garima ;

Kosiborod, Mikhail N. ;

Vaduganathan, Muthiah ;

Neilan, Tomas G. ;

Lopez, Teresa ;

Dent, Susan ;

Baldassarre, Lauren ;

Scherrer-Crosbie, Marielle ;

Barac, Ana ;

Liu, Jennifer ;

Deswal, Anita ;

Khadke, Sumanth ;

Yang, Eric H. ;

Ky, Bonnie ;

Lenihan, Daniel ;

Nohria, Anju ;

Dani, Sourbha S. ;

Ganatra, Sarju .

JACC-HEART FAILURE, 2024, 12 (01) :67-78

[4] Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose-lowering medications [J].

Bell, David S. H. ;

Goncalves, Edison .

DIABETES OBESITY & METABOLISM, 2019, 21 (06) :1277-1290

[5] Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti-diabetic therapies [J].

Bell, David S. H. ;

Goncalves, Edison .

DIABETES OBESITY & METABOLISM, 2019, 21 (02) :210-217

[6] The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure [J].

Berezin, Alexander A. ;

Obradovic, Zeljko ;

Fushtey, Ivan M. ;

Berezina, Tetiana A. ;

Novikov, Evgen V. ;

Schmidbauer, Lukas ;

Lichtenauer, Michael ;

Berezin, Alexander E. .

BIOMEDICINES, 2023, 11 (02)

[7] Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF [J].

Bode, David ;

Semmler, Lukas ;

Wakula, Paulina ;

Hegemann, Niklas ;

Primessnig, Uwe ;

Beindorff, Nicola ;

Powell, David ;

Dahmen, Raphael ;

Ruetten, Hartmut ;

Oeing, Christian ;

Alogna, Alessio ;

Messroghli, Daniel ;

Pieske, Burkert M. ;

Heinzel, Frank R. ;

Hohendanner, Felix .

CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)

[8] Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): rationale and design [J].

Carberry, Jaclyn ;

Petrie, Mark C. ;

Lee, Matthew M. Y. ;

Brooksbank, Katriona ;

Campbell, Ross T. ;

Good, Richard ;

Jhund, Pardeep S. ;

Kellman, Peter ;

Lang, Ninian N. ;

Mangion, Kenneth ;

Mark, Patrick B. ;

McConnachie, Alex ;

McMurray, John J. V. ;

Meyer, Barbara ;

Orchard, Vanessa ;

Shaukat, Aadil ;

Watkins, Stuart ;

Welsh, Paul ;

Sattar, Naveed ;

Berry, Colin ;

Docherty, Kieran F. .

ESC HEART FAILURE, 2024, 11 (04) :2001-2012

[9] New insights into the molecular mechanisms of SGLT2 inhibitors on ventricular remodeling [J].

Chen, Yang ;

Peng, Daoquan .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 118

[10] Softening the Stiff Heart SGLT2 Inhibition and Diastolic Function [J].

Connelly, Kim ;

Cai, Sean .

JACC-CARDIOVASCULAR IMAGING, 2021, 14 (02) :408-410

← 1 2 3 4 5 6 7 →